Erectile dysfunction following intravitreal bevacizumab
MEAJO-Middle East African Journal of Ophthalmology. 2010; 17 (3): 281-284
em Inglês
| IMEMR
| ID: emr-123607
ABSTRACT
Despite initial concerns regarding systemic complications, the use of intravitreal antivascular endothelial growth factor [anti-VEGF] agents for ocular disease is rapidly expanding worldwide, in terms of both the number of patients injected and its indications. To our knowledge, there are no cases in the literature reporting erectile dysfunction following the use of intravitreal bevacizumab. We postulate an organic mechanism for impaired erectile function due to systemically absorbed intravitreal bevacizumab. We describe a case of erectile dysfunction following intravitreal bevacizumab administration. Color fundus photos, fluorescein angiogram and optical coherence tomography images are presented. A 40-year-old male underwent intravitreal bevacizumab therapy for macular edema secondary to a branch retinal vein occlusion. He subsequently developed transient erectile dysfunction after each of his two bevacizumab injections. His only comorbidity was mild hypertension. Erectile dysfunction may be a side effect of intravitreal bevacizumab. The erectile dysfunction could be organic and/or psychogenic in etiology
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Corpo Vítreo
/
Oclusão da Veia Retiniana
/
Angiofluoresceinografia
/
Edema Macular
/
Fator A de Crescimento do Endotélio Vascular
/
Tomografia de Coerência Óptica
/
Anticorpos Monoclonais
Tipo de estudo:
Relato de Casos
Limite:
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Middle East Afr. J. Ophthalmol.
Ano de publicação:
2010
Similares
MEDLINE
...
LILACS
LIS